Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010707 · ClinicalTrials.gov registry record · Phase 2
Transgender Estradiol Affirming Therapy
A Phase 2 study of Transgenderism, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05010707: Completed Phase 2 study of Transgenderism, sponsored by Washington University School of Medicine.
NCT05010707 is a Phase 2 study of Transgenderism that has completed, run by Washington University School of Medicine. The registered enrollment target is 39 participants, below the 62-participant average among 5 other Transgenderism trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05010707, a Phase 2 study of Transgenderism, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
Primary Outcome
Degree of testosterone suppression by measuring total testosterone level in transgender female patients undergoing hormonal affirming therapy, clinical testosterone level in pg/mL
Conditions Studied
Interventions
- DRUG Transdermal patch
- DIAGNOSTIC_TEST Pro-thrombotic markers
- DIAGNOSTIC_TEST Metabolic markers
- DIAGNOSTIC_TEST Hormone Profile
- DRUG Daily Sublingual Tablet
Study Locations (1)
Missouri
- Washington University Transgender Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 2 |
What the finished NCT05010707 record still lists
NCT05010707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 62-participant average among 5 other Transgenderism trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Transgenderism appearing as the primary indexed condition, and to 5 interventions - of which Transdermal patch is the first listed.
NCT05010707 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05010707 about?
NCT05010707 is a clinical study titled "Transgender Estradiol Affirming Therapy". The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
What is the current status of trial NCT05010707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2021-08-02. Estimated completion is 2024-01-01.
What conditions does trial NCT05010707 study?
This clinical trial studies the following conditions: Transgenderism.
What interventions are being tested in trial NCT05010707?
The interventions under investigation include: Transdermal patch (DRUG), Pro-thrombotic markers (DIAGNOSTIC_TEST), Metabolic markers (DIAGNOSTIC_TEST), Hormone Profile (DIAGNOSTIC_TEST), Daily Sublingual Tablet (DRUG).
Who is sponsoring clinical trial NCT05010707?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010707 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgenderism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puberty Suppression and Cardiometabolic Health
RECRUITING
-
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
RECRUITING · Phase 4
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Cardiometabolic Health in Transgender Males
ACTIVE NOT RECRUITING
-
Effect of Hormone Therapy on Renal Function
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI